Stockscreener 앱 받기
1.15
5.74%
-0.07
시간 외 거래:
1.15
전일 마감가:
$1.22
열려 있는:
$1.18
하루 거래량:
758.96K
Relative Volume:
1.14
시가총액:
$72.55M
수익:
$139.77M
순이익/손실:
$-97.62M
주가수익비율:
-0.7278
EPS:
-1.58
순현금흐름:
$-61.71M
1주 성능:
-22.30%
1개월 성능:
-49.56%
6개월 성능:
-67.61%
1년 성능:
-91.59%
1일 변동 폭
$1.10
$1.19
1주일 범위
$1.10
$1.51
52주 변동 폭
$1.10
$19.54
Macrogenics Inc Stock (MGNX) Company Profile
명칭
Macrogenics Inc
전화
301-251-5172
주소
9704 MEDICAL CENTER DRIVE, Rockville, MD
MGNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.15 | 72.55M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-07 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-07-31 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-05-10 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-05-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-04-26 | 개시 | B. Riley Securities | Buy |
| 2024-04-09 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-03-04 | 재확인 | BTIG Research | Buy |
| 2024-02-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-11-22 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-11-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-02-28 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-04 | 개시 | SMBC Nikko | Outperform |
| 2021-11-17 | 재개 | Guggenheim | Buy |
| 2021-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-12 | 업그레이드 | Barclays | Underweight → Overweight |
| 2020-12-22 | 재개 | H.C. Wainwright | Buy |
| 2020-08-03 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-06-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Underweight |
| 2019-12-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-11-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | 재개 | Guggenheim | Neutral |
| 2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-04-12 | 개시 | Guggenheim | Neutral |
| 2019-02-07 | 업그레이드 | Citigroup | Sell → Buy |
| 2019-02-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-02-06 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-12-10 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-05-31 | 개시 | Evercore ISI | Outperform |
| 2018-03-05 | 개시 | H.C. Wainwright | Buy |
| 2017-03-31 | 개시 | Raymond James | Outperform |
모두보기
Macrogenics Inc 주식(MGNX)의 최신 뉴스
MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
MacroGenics, Inc. (NASDAQ:MGNX) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Has $540,000 Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
HC Wainwright Increases Earnings Estimates for MacroGenics - Defense World
MacroGenics, Inc. (MGNX) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
MacroGenics (NASDAQ:MGNX) Price Target Lowered to $2.00 at HC Wainwright - Defense World
MGNX stock touches 52-week low at $1.88 amid market challenges - Investing.com Australia
MGNX stock touches 52-week low at $1.88 amid market challenges By Investing.com - Investing.com South Africa
MacroGenics stock target cut to $2 at H.C. Wainwright By Investing.com - Investing.com Canada
Extensive-Stage Small Cell Lung Cancer (ESCLC) Clinical - openPR.com
Macrogenics Inc (NASDAQ: MGNX) Analysts Prediction On How Much It Could Rise - Stocks Register
MacroGenics, Inc. (NASDAQ:MGNX) Receives $7.63 Consensus Price Target from Analysts - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2024 Earnings Call Transcript - Insider Monkey
MacroGenics’ SWOT analysis: pipeline progress, cash runway extend stock outlook - Investing.com Canada
StockNews.com Downgrades MacroGenics (NASDAQ:MGNX) to Hold - Defense World
MacroGenics’ SWOT analysis: pipeline progress, cash runway extend stock outlook By Investing.com - Investing.com South Africa
MacroGenics Inc’s 2024 Earnings Call Highlights - TipRanks
MacroGenics axes ADC drug following Phase II failure in prostate cancer - Yahoo
Macrogenics Inc (MGNX) Q4 2024: Everything You Need to Know Ahea - GuruFocus.com
Stifel maintains Hold on MacroGenics stock, price target at $6 By Investing.com - Investing.com Canada
Citizens JMP maintains MacroGenics stock with Market Outperform By Investing.com - Investing.com South Africa
Citizens JMP maintains MacroGenics stock with Market Outperform - Investing.com India
MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates - MSN
MacroGenics Reports 2024 Financial Results and Progress - TipRanks
Macrogenics Inc (MGNX) Q4 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses - Yahoo Finance
MacroGenics (MGNX) Q4 2024 Earnings Call Transcript - Yahoo
MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
MACROGENICS Earnings Results: $MGNX Reports Quarterly Earnings - Nasdaq
Earnings call transcript: MacroGenics beats Q4 2024 EPS expectations - Investing.com India
Earnings call transcript: MacroGenics beats Q4 2024 EPS expectations By Investing.com - Investing.com UK
MacroGenics Inc. (MGNX) reports earnings - Quartz
MacroGenics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MacroGenics Inc Provides Update On Corporate Progress And 2024 Financial Results - Marketscreener.com
Macrogenics Inc (MGNX) Reports Q4 Revenue of $150 Million, Surpa - GuruFocus
MACROGENICS INC SEC 10-K Report - TradingView
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results - GlobeNewswire
MacroGenics Triples Revenue to $150M as Cancer Drug Pipeline Advances - StockTitan
MGNX stock touches 52-week low at $2.15 amid sharp annual decline - Investing.com Australia
Macrogenics Stock Drops 77% After Study Deaths - The Wall Street Journal
Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire
MacroGenics (MGNX) to Release Quarterly Earnings on Thursday - Defense World
MacroGenics at Barclays Conference: Strategic Insights on Pipeline and Partnerships By Investing.com - Investing.com South Africa
MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
MacroGenics at Barclays Conference: Strategic Insights on Pipeline and Partnerships - Investing.com
MGNX Deadline: MGNX Investors with Losses in Excess of $100K Hav - GuruFocus.com
MacroGenics at Leerink’s Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
MacroGenics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before September 24, 2024 to Discuss Your RightsMGNX - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc. (MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Macrogenics Inc (MGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):